31
Jan
2012
Groove Biopharma, Inc.: Series B $6M
Posted in I - Series B, Q - 4Q11, R - NORTH WEST, X - Antiinfective, X - Fibrosis, X - Oncology, X - miRNA, XX - WA
Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.
05
Oct
2011
Theraclone Sciences, Inc.: Series B $10.6M
Posted in I - Series B, Q - 3Q11, R - NORTH WEST, X - Antibody, X - Antiinfective, X - Inflammation, XX - WA
Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.
02
Aug
2011
28
Jul
2011
TetraLogic Pharmaceuticals, Inc.: Series C $6M
Posted in I - Series C, Q - 2Q11, R - NORTH EAST, X - Oncology, XX - PA
TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage pharmaceutical company developing novel small molecule drugs to treat cancer, closed a $6M Series C financing bringing the total round to $43M. Participants include Nextech Invest, Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, Vertical Group and Amgen Ventures.
20
May
2011
TetraLogic Pharmaceuticals, Inc.: Series C $23M
Posted in I - Series C, Q - 1Q11, R - NORTH EAST, X - Oncology, XX - PA
TetraLogic Pharmaceuticals (Malvern, PA) a clinical-stage biopharmaceutical company developing novel small molecule drugs to treat cancer, closed a $23M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Pfizer Venture Investments, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures, The Vertical Group and Amgen Ventures.
18
Jan
2011
Acylin Therapeutics, Inc.: Series A $4.4M
Posted in I - Series A, Q - 4Q10, R - NORTH WEST, X - CNS, X - Metabolism, X - Oncology, XX - WA
Acylin Therapeutics (Seattle, WA) a development-stage biopharma company focused on inhibiting histone acetyltransferase in cancer, metabolic disease, and neurodegeneration indications, closed a $4.4M Series F financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD and Washington Research Foundation Capital.
30
Nov
2010
Sutro Biopharma, Inc.: Series C $36.5M
Posted in I - Series C, Q - 4Q10, R - WEST, X - Therapeutic Platform, XX - CA
Sutro Biopharma (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on partnering and developing proprietary protein therapeutics that have site directed modifications, closed a $36.5M Series C financing. Participants include Skyline Ventures, Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners.
04
Oct
2010
19
Aug
2010
TetraLogic Pharmaceuticals, Inc.: Series C $32M
Posted in I - Series C, Q - 3Q10, R - NORTH EAST, X - Apoptosis, X - Necrosis, XX - PA
TetraLogic Pharmaceuticals (Malvern, PA) a preclinical-stage small molecule company focused on apoptosis and necrosis modulation for potential cancer, cardiovascular, neurological and ophthalmic disease treatment, closed a $32M Series C financing. Participants include Clarus Ventures, Hatteras Venture Partners, Amgen Ventures, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group.
16
Aug
2010
Calistoga Pharmaceuticals, Inc.: Series C $40M
Posted in I - Series C, Q - 3Q10, R - NORTH WEST, X - Inflammation, X - Oncology, X - PI3K, XX - WA
Calistoga Pharmaceuticals (Seattle, WA) a clinical-stage small molecule company focused on isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases, closed a $40M Series C financing. Participants include Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners.
05
Feb
2010
Epizyme, Inc.: Series B $8M
Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA
Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 [...]
20
Jan
2010
Epizyme, Inc.: Series B $32M
Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, X - Therapeutic Platform, XX - MA
Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications. Participants include Bay City Capital, Amgen Ventures, Astellas Venture Management, MPM Capital and Kleiner Perkins Caufield and Byers.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.
OnBioVC PARTNERS
-
